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Abstract 
Metabolomic profiling is ideally suited for the analysis of cardiac metabolism in healthy and diseased 
states. Here, we show that systematic discovery of biomarkers of ischemic preconditioning using 
metabolomics can be translated to potential nanotheranostics. Thirty-three patients underwent 
percutaneous coronary intervention (PCI) after myocardial infarction. Blood was sampled from 
catheters in the coronary sinus, aorta and femoral vein before coronary occlusion and 20 minutes 
after one minute of coronary occlusion. Plasma was analysed using GC-MS metabolomics and 
iTRAQ LC-MS/MS proteomics. Proteins and metabolites were mapped into the Metacore net-
work database (GeneGo, MI, USA) to establish functional relevance. Expression of 13 proteins was 
significantly different (p<0.05) as a result of PCI. Included amongst these was CD44, a cell surface 
marker of reperfusion injury. Thirty-eight metabolites were identified using a targeted approach. 
Using PCA, 42% of their variance was accounted for by 21 metabolites. Multiple metabolic 
pathways and potential biomarkers of cardiac ischemia, reperfusion and preconditioning were 
identified. CD44, a marker of reperfusion injury, and myristic acid, a potential preconditioning 
agent, were incorporated into a nanotheranostic that may be useful for cardiovascular applications. 
Integrating biomarker discovery techniques into rationally designed nanoconstructs may lead to 
improvements in disease-specific diagnosis and treatment. 
Key words: metabolomics, silicon quantum dots, theranostics, cardiac ischemia, myocardial in-
farction. 
Introduction 
The heart is highly metabolic and consumes 
more energy than any other organ.[1] Unsurprisingly, 
cardiac energetics and metabolism is an area of in-
tense study. Metabolomic profiling takes a 
high-throughput, global approach and screens thou-








geted methods. Due to its agnostic approach, and 
breadth of observation, its strength is in identifying 
novel pathways, not previously associated with dis-
ease.[2-4]  
Metabolomics and proteomics have been applied 
to biomarker discovery for diseases such as myocar-
dial infarction.[5] Although integrating data from 
both of these methods has been performed, published 
research in this area is rare.[6] Whilst biomarker dis-
covery is one use for this method, the ideal goal is the 
elucidation of pathways for drug targeting or com-
pound discovery for therapeutic applications. 
Integrating drugs and imaging agents into a sin-
gle platform to create theranostics has become a 
highly active area of research because it may enable 
earlier detection and treatment of diseases and may 
allow the assessment of patient response to therapy. 
To this end, nanoplatforms are actively being inves-
tigated as delivery vehicles for theranostics because 
they can readily incorporate multiple active agents 
(drugs, dyes, quantum dots, etc) in their core or on 
their surface. In addition to incorporation of multiple 
functionalities, nanotechnology platforms have 
shown the potential to reduce the side effects of free 
drug molecules by enhancing delivery to a specific 
targeted site, increasing the circulation time, and im-
proving the toxicity profile of the drug. Rational de-
sign of nanocarriers allows for their functionalization 
with targeting agents that promote localization of the 
nanoplatforms at a disease site. Combining the 
strengths of proteomics and metabolomics with those 
of nanoplatforms enables the acquisition of rich in-
formation directly from patient samples to be trans-
lated into theranostics that can then be evaluated in 
suitable candidates. This approach may have real im-
plications for personalized medicine when extended 
to single patients. 
Recent developments in optical imaging provide 
quantitative information that offers interesting possi-
bilities for in vivo diagnosis and monitoring of treat-
ment efficacy in cancer and other various diseases.[7] 
The advantages of optical imaging are that is uses 
non-ionizing radiation and has high spatial resolu-
tion. The strategy of creating multifunctional optical 
systems for diagnosis, treatment and monitoring of 
cancer has been explored by several groups. Optical 
imaging has been separately combined with chemo-
therapy, photodynamic therapy, photothermal ther-
apy, and gene therapy. It has also been combined with 
MRI agents and therapeutics to allow for multimodal 
imaging and therapy. The investigations of optical 
based theranostic platforms show promising potential 
for cancer treatment and diagnosis. The benefit of 
multifunctional nanomedicines in cancer is also rele-
vant to cardiovascular diseases (CVDs) as there are 
many commonalities to the two disease entities. 
McCarthy et al reported the use of a light-activated 
theranostic nanoagent for targeted macrophage abla-
tion in inflammatory atherosclerosis.[8] Their ap-
proach showed promise for detection and treatment 
of atherosclerotic lesions. Creating CVD theranostics 
is highly desirable; however, limited information on 
the active agents and targeting sites is presently 
available.  
Quantum dots are light emitting semiconductor 
spheres 1-10nm in diameter and have been investi-
gated as the optical component of theranostics, but 
investigations have been limited by toxicity concerns. 
The toxicity concerns are associated with the presence 
of heavy metals in first generation of quantum dots 
(e.g. CdSe-based QDs). This toxicity concern can be 
largely eliminated by using silicon quantum dots 
(SiQDs). SiQDs have been shown to be a promising 
non-toxic candidate for imaging and multimodal ap-
plications.[9] SiQDs have been investigated as imag-
ing agents because they have bright emission, tunable 
luminescence color, and low toxicity. Significant 
demonstrations with SiQDs have been made in bio-
logical applications such as tumor targeting, sentinel 
lymph node mapping, and multicolor imaging. In this 
paper, we demonstrate the potential of integrating 
metabolomic and proteomic data in a human model of 
cardiac ischemia and preconditioning. We then 
translated this into a potential therapeutic diagnostic 
(theranostic), using a multimodal non-toxic nanoim-
aging agent (i.e. SiQDs, FDA approved F127 and 
DSPE-PEG-Amine) combined with compounds iden-
tified in the metabolomics analysis. Using data di-
rectly obtained from human models for the immediate 
fabrication of a theranostic nanoconstruct is a novel, 
highly multidisciplinary approach that has a strong 
potential to be adopted on the pathway to personal-
ized medicine. 
Materials and Methods  
This study was approved by the Northern Re-
gional Ethics Committee for New Zealand. 33 patients 
gave informed consent to be enrolled into the trial. 
Patients with a first non ST elevation myocardial in-
farction and serum troponin T >0.1 mmol/l under-
going coronary angiography between 24 hours and 
six days following were screened.  
Exclusion criteria included: acute myocardial 
infarction within the preceding 24 hours, haemody-
namic instability (including cardiogenic shock, sys-
tolic blood pressure <100 mmHg, uncontrolled heart 
failure or significant LV impairment (EF <35 per-
cent)), significant (moderate-severe) valvular disease, 




renal impairment (creatinine >0.16 mmol/l), occluded 
vessel or extensive angiographic thrombus on diag-
nostic angiography. 
All non-study medications including use of 
heparins, direct thrombin inhibitors, clopidogrel and 
glycoprotein IIb/IIIa inhibitors were administered at 
the discretion of the leading physician.  
Study procedure 
Baseline angiography was performed in the 
usual manner. Baseline blood samples were simulta-
neously taken from the great cardiac vein and as-
cending aorta. Angioplasty was then performed with 
a mandated initial predilatation of 60 seconds, unless 
otherwise indicated on clinical grounds. 20 minutes 
after the first balloon inflation a final blood sample 
was taken from the great cardiac vein (CS), ascending 
aorta (AO) and femoral vein.  
Laboratory Procedures 
Metabolomics GC-MS analysis 
Metabolites were extracted according to an op-
timised protocol developed by the Villas-Bôas labor-
atory. A methyl chloroformate (MCF) derivatization 
was performed according to Villas-Bôas et al.[10] 
GC-MS analysis was undertaken according to the 
parameters established by Villas-Bôas & Bruheim.[11]  
Metabolite identification 
 The approach for metabolite identification was 
developed by the Villas-Bôas laboratory[12] and is 
summarised as follows; metabolites in the samples 
were identified using our in-house MCF MS library of 
derivatized metabolites. The library contains MS 
spectra obtained from ultra-pure standards that have 
been derivatized, with the mass spectrum saved in the 
AMDIS 2.65 software (www.amdis.net). The relative 
level of the metabolites was based on the base peak 
height. Values were normalised by the base peak 
height of the internal standard (d4-alanine). A me-
tabolite profile for each sample was thus built up and 
subjected to further analyses as described below. 
Proteomics substudy (n=8)  
Blood was collected into 5 ml EDTA (ethylene-
diaminetetraacetic acid) vacutainer tubes (Becton, 
Dickinson and Company) and plasma extracted by 
centrifugation within 2 minutes of collection.  
Depletion of plasma samples 
To allow for detection of moderately abundant 
plasma proteins, plasma samples were depleted of the 
12 most abundant proteins using the ProteomeLab 
IgY-12 High Capacity SC Spin Column Kit (Beckman 
Coulter), according to the instructions provided by 
the manufacturer.  
Sample preparation and liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) 
Depleted samples were prepared for iTRAQ la-
beling according to our previously devised procedure 
[13] with some modification. Protein concentrations 
were determined using the Bradford method (Bio-
Rad). Digested plasma protein from each preparation 
was labeled with 4-plex iTRAQ reagent, according to 
the manufacturer’s description. The combined pools 
of iTRAQ-labeled samples were then fractioned by 
on-line cation exchange using 15 salt steps and the 
resulting LC effluent was directed into the ion spray 
source of a QSTAR XL hybrid mass spectrometer 
(Applied Biosystems, Foster City, CA) set to scan from 
300 to 1600 m/z and with the top three most abundant 
multiply charged peptides selected for MS/MS anal-
ysis (80–1600 m/z). Protein Pilot 1.0 software (Applied 
Biosystems, Foster City, CA) was then used with the 
“rapid” search effort to search the output data against 
the human IPI v3.27 database with carbamidomethyl 
cysteine as fixed modification and trypsin as the en-
zyme specificity.  
Statistics and Bioinformatics 
Proteomic data analysis 
The significance of the protein expression 
changes were determined using a two-tailed Student’s 
t-test assuming unequal variance, p<0.05 was consid-
ered significant and p<0.10 was considered trending. 
Further to this first pass analysis, proteins found to 
change with p<0.10 were subjected to a second test in 
order to predict the relevance of these findings across 
patients, i.e. their potential usefulness as biomarkers. 
For this, protein log ratios were obtained for each 
post-PCI versus the non-corresponding pre-PCI value 
analyzed within the same LC-MS/MS run. Signifi-
cance was then determined using an unpaired 
two-tailed Student’s t-test assuming unequal vari-
ance, p<0.05 was considered significant and p<0.10 
was considered trending.  
Metabolomic data analysis 
The metabolomic data was initially transformed 
using Principal Component Analysis (PCA) before 
bioinformatic methods were applied. A signal to noise 
(SNR) method was used to rank data from most im-
portant to least important based on SNR.  
𝑆𝑁𝑅(𝑋) =  |𝑚𝑒𝑎𝑛(𝑥𝑎) −𝑚𝑒𝑎𝑛(𝑥𝑏)|
𝑠𝑡𝑑(𝑥𝑎) + 𝑠𝑡𝑑(𝑥𝑏)  
(Where xa are the values of variable X belonging to 




class A and xb are the variables of belonging to class 
B). 
The data was pre-processed (missing values 
filled in, normalization) and then split several times 
(three to six folds cross validation) into a training part 
(e.g. 70 percent) and test part (e.g. 30 percent). Fea-
tures were extracted and ranked from the training 
part and then these features and the training data 
were used to build a personalized model (PM) for 
every sample from the test data.  
Functional analysis 
The proteins and metabolites that featured 
commonly between the first principal component and 
the bioinformatic methods, used above, were mapped 
into the Metacore network database (GeneGo, MI, 
USA). Genes known to interact with or affected by the 
key metabolites from comparative toxicogenomics 
studies were also included in the analysis. 
Preparation of Theranostic Nanoconstructs 
Synthesis of silicon nanoparticles 
 Luminescent silicon nanoparticles were synthe-
sized as detailed in previous reports [14]. Non lumi-
nescent powders were synthesized by laser pyrolysis, 
etched with a 10:1 hydrofluoric acid:nitric acid mix-
ture to obtain luminescence, and functionalized with 
ethyl undecylenate by UV initiated hydrosilylation. 
The samples were then stored for further use. 
Synthesis of theranostic nanoconstructs 
The silicon quantum dots, myristic acid (Al-
drich), Pluronic® F127 (BASF) and DSPE PEG amine 
(Avanti Polar Lipids) were suspended in chloroform 
(1:0.3:19:1, w/w ratio) and sonicated. The chloroform 
was evaporated using a Labconco rotary evaporator, 
leaving a lipidic film. The film was sonicated in HPLC 
grade water to form a micellar suspension. In subse-
quent experiments, the nanoconstructs were conju-
gated to hyaluronic acid (Lifecore Biomedical LLC) 
via EDC chemistry to form an amide bond between 
carboxyl groups on the hyaluronic acid and the amine 
groups of the DSPE-PEG amine. The particles were 
washed three times and stored for further use. 
Results 
Proteomics 
The initial analysis of changes within patients 
identified 31 proteins as significantly different be-
tween pre- and post-PCI samples (p<0.05). A second 
analysis identified 27 proteins as significantly differ-
ent (p<0.05). Combining the information from the two 
analyses revealed 13 proteins, displayed in Table 1, 
which exhibited absolute consistency and which 
changed with p<0.10 in both analyses. Of these, four 
decreased by PCI had calculated ratios (post-PCI Vs 
pre-PCI, paired and crossed) consistently lower than 
<0.6, and a further three proteins were increased with 
all ratios > 1.4.  
 
 
Table 1. Protein expression changes due to percutaneous coronary intervention (PCI). 
Protein Name IPI Accession average pre-PCI 
Vs post-PCI 
(paired) 
Range of ratios average pre-PCI Vs 
post-PCI 
(crossed) 
Range of ratios 
   Min Max  Min Max 
Thyroxine-binding globulin IPI00292946.1 0.26 0.11 0.52 0.25 0.15 0.46 
Alpha-1-acid glycoprotein 2 IPI00020091.1 0.37 0.19 0.94 0.37 0.15 0.90 
Complement C1r-like protein IPI00009793.3 2.47 1.54 5.85 2.47 1.40 4.92 
Isoform 1 of Complement factor B IPI00019591.1 1.98 1.24 3.19 1.98 1.16 6.98 
CD44 antigen IPI00828192.1 5.10 1.79 14.41 5.10 1.70 15.18 
Isoform 1 of Alpha-1-antichymotrypsin  IPI00550991.3 0.08 0.03 0.19 0.08 0.02 0.23 
Alpha-2-antiplasmin IPI00029863.4 0.24 0.07 0.92 0.24 0.05 0.91 
Kallistatin IPI00328609.3 0.17 0.09 0.47 0.13 0.02 0.82 
Heparin cofactor 2 IPI00292950.4 0.12 0.07 0.23 0.12 0.04 0.35 
Isoform HMW of Kininogen-1 IPI00032328.2 0.06 0.03 0.13 0.06 0.02 0.10 
Apolipoprotein(a) IPI00739995.2 3.70 2.19 5.52 3.70 1.77 5.32 
Apolipoprotein B-100 IPI00022229.1 0.42 0.22 0.75 0.42 0.12 1.00 
Alpha-1B-glycoprotein precursor IPI00745089.2 2.14 1.22 4.20 2.14 1.32 2.86 
Min and max ratios (paired and crossed comparisons) for the 13 proteins that exhibited absolute consistency and changed with p<0.10 in both analyses. In bold 
are four decreased proteins where the highest individual post-PCI vs. pre-PCI ratio (paired or crossed) was below 0.6, and three increased proteins where the 
lowest post-PCI Vs pre-PCI ratio (paired or crossed) was at least 1.40. 
 





Obtaining reliable antibodies for most of the 
proteins of interest was difficult and therefore re-
stricted confirmation of the proteomic results by 
western blotting to ceruloplasmin (CP). The behavior 
of CP levels in non-depleted plasma was largely con-
sistent with the proteomic findings in that seven of the 
eight patients showed a marked decrease in CP levels 
post-PCI.  
Metabolomics 
Principal components analysis showed that 31 
metabolites accounted for 42 percent of the variance 
in the results. 21 of these metabolites, in the first PCA 
(Table 2, Figure 1), were cross-referenced with the 
metabolites identified by the highest signal to noise 
ratio in the coronary sinus plasma dataset. 12 com-
mon metabolites (Table 3) were used for the func-
tional analysis. 
The scores plot of the first three PCs, describe 48 
percent of the variance in the data, and the separation 




Fig 1. 3D score plot for coronary sinus samples at baseline and post 
procedure (an enlarged image is included in supporting information.) 
 
 

















Aspartic acid  
Glutamic acid  
Pyroglutamic acid  
Alanine  
Myristic acid  
Cysteine  
Lactic acid  
 
Table 3. Common 12 features seen between PCA1 and SNR 
ranking of coronary sinus plasma. 
 
 






Discriminatory analysis using bioinformatics 
was applied to systemic blood taken from the aorta. 
Three methods were used, including wKNN classifi-
cation model, a SVM classification method and an 
evolving spiking neural network classification model 
(eSNN). After 1,000 iterations of the algorithm a dis-
criminatory accuracy of 81 percent was made. 11 fea-
tures were identified using these models, five were 
common with the metabolites identified by PCA1 and 
SNR from the coronary sinus dataset. The potential 
biomarkers identified by bioinformatics analysis of 
aortic blood and cross-referenced with coronary sinus 
were methyl-2-oxopentanoicacid, serine, tryptophan, 
oleic acid and *myristic acid. Structures of all mole-
cules are listed in Supplementary Material: table S1. 
Functional network analysis 
Cross-referencing proteins, metabolites and pu-
tative genes identified a number of pathways of in-
terest (Figure 2 and Legend). These included; immune 
response, clotting cascade, steroid, lipid, cholesterol 
and sterol metabolic processes as well as vLDL parti-
cle assembly. General biomarkers fell into the catego-
ries of glucose metabolism disorders, hyperinsulin-
ism, nutritional and metabolic disorders. The top five 
diseases associated with the key metabolites and in-
teracting genes included; myocardial ischemia, glu-
cose metabolism, metabolic disorders, vascular dis-
eases and eye disease. Statistically significant path-
ways and process networks showed glutathione me-
tabolism, and EDG3 and EDG1 signaling pathways to 
be involved as well as networks related to hypoxia 
and oxidative stress, signal transduction ESR2, in-
flammation and complement system, immune re-
sponse – phagocytosis, cell adhesion (plate-
let-endothelium-leukocyte interactions), translational 
selenium pathway, cell cycle G1-5 growth factor reg-
ulation, cell adhesion glycoconjugates, signal trans-
duction WNT signaling and cytoskeleton regulation 
and rearrangement.  
To fabricate a theranostic based on the infor-
mation from the metabolomics study, the myristic 
acid and silicon quantum dots were encapsulated in 
the core of a micelle composed of a mixture of Plu-
ronic ® F127 and DSPE-PEG-NH2. Hyaluronic acid, 
capable of targeting CD44, was bioconjugated to the 
surface of the nanoparticle by creating peptide bonds 
between the carboxyl group and the amine groups of 
the DSPE-PEG-NH2. Figure 3a depicts a schematic 
showing the components of the potential theranostic. 
Transmission electron microscopy images in Figure 
3b show that the theranostic is near-spherical and 
about 100 nm or less in diameter. Upon close obser-
vation in figure 3c, crystalline silicon is observed 
(Supplementary Material: Figure S2 has a larger im-
age to allow lattice fringes to be observed clearly). The 
silicon nanoparticles are dispersed throughout the 
micelle, not densely packed. This is attributed to the 
presence of myristic acid. The emission of the silicon 
is at 700 nm as seen in Figure 3d. This is a particularly 
good emission wavelength for biological imaging 
because biological samples have the highest trans-
parency between 700 nm and 900 nm. FTIR confirms 
the attachment of hyaluronic acid to the surface of the 
micelles, as shown in figure 3e. The red line shows the 
spectra of silicon nanoconstructs before bionconjuga-
tion. It has characteristic peaks around for amines 
around 3300 cm-1 and CH bending around 2800 cm-1. 
The blue line shows spectra after bioconjugation and 
suggests that hyaluronic acid is bound to the surface 
of the micelle, because the OH peak of hyaluronic acid 
becomes more prominent around 3400 cm-1 and 1000 
cm-1, and the CH peaks associated with DSPE-PEG 
decrease. Preliminary release analysis by HPLC indi-
cates that 3.7% of the myristic acid was released from 
the micelle in 3 hours. The targeting ability of the 
particles to CD44 was evaluated by targeting them to 
pancreatic cancer cells with CD44 receptors [15]. The 
signal from the silicon quantum dots was readily 
seen. 
Discussion 
This exploratory experiment of coronary angio-
plasty identified altered expression in a number of 
proteins and metabolites. Furthermore merging the 
metabolite and proteomic data in a network analysis 
identified pathways and disease mechanisms con-
sistent with the perturbation being examined, that 
being cardiac ischemia. A number of the changes seen 
were probably the result of heparin administration 
(e.g. antithrombin III, beta-2-glycoprotein 1, hy-
droxybutyrate) [16] however the key features of CD44 
and various fatty acids were notable.  
CD44 appeared as an interesting potential di-
agnostic biomarker for ischemia/reinfarction in this 
study. An independent proteomics study by Addona 
et al has also showed upregulation of CD44 in patients 
undergoing alcohol induced myocardial infarction 
[17]. CD44 antigen has been shown to be up-regulated 
in response to ischemic injury of the kidney as well as 
myocardial infarct and it may mediate infarct healing 
through the regulation of inflammatory and fibrotic 
responses [18]. CD44 is expressed on a number of cell 
types including not only solid organs but also neu-
trophils, macrophages and bone marrow derived 




mesenchymal stem cells (MESCs).[19] The multifunc-
tional CD44 antigen is a hyaluronan receptor primar-
ily involved in cell-cell and cell-matrix interactions. 
Hyaluronic acid, the ligand for CD44, appears critical 
in the localisation of MESCs after ischemic injury. It 
has been suggested that CD44 represents an interest-
ing drug target and disruption of CD44 appears to 
protect against renal reperfusion injury in rats.[20] 
Hence we considered it worthwhile to develop a 
theranostic nanocontruct, using CD44 as the target 
molecule.[21] 
 
Fig 2. Processes identified amongst key metabolites and proteins. An enlarged version of this image is available in the supporting information. 





Fig 3. Composite diagram containing formulation schematic, TEM, photoluminescent emission, and FTIR spectra. (a) schematic of 
theranostic nanoconstruct (further details of self-assembly of lipid micelles are shown in Supplementary Material: Figure S1); (b) low-resolution TEM of 
nanoconstructs; (c) high resolution TEM showing crystalline Si nanocrystals within the constructs (larger image is shown in Supplementary Material: Figure 
S2); (d) photoluminescence emission spectrum of nanoconstructs; and (e) FTIR spectra of nanoconstructs before (red) and after (blue) conjugation with 
hyaluronic acid. 
 
The metabolomic network analysis revealed a 
number of interesting findings with converging func-
tional relevance. Both myristic and oleic acid demon-
strated a functional connectivity with mechanisms 
related to peroxisome proliferator-activated receptor 
gene (alpha, beta, gamma) function (PPARs). This 
mechanism has similarly been shown to be important 
using metabolomic analysis of serum in patients fol-
lowing myocardial infarction.[22] Myristic acid itself 
has previously been shown to act as a protective agent 
against reperfusion injury in vitro[23], as a result of 
preconditioning. Preconditioning is caused by a en-
dogenous humoral factor, probably a small molecule, 
and can be transferred between animals and species, 
using dialysate from treated animals.[24-26] Myristic 
acid has been shown to have active biological proper-
ties when administered ex vivo. Myristic, pentadeca-
noic, palmitic, and palmitoleic acid cause downregu-




lation of TNF-alpha, via PPAR agonism, in inflam-
matory diseases such as falciparum malaria 
infection.[27] We hypothesized that myristic acid may 
be physiologically active in the context of ischemia 
and therefore developed a theranostic micelle using 
hyaluronic acid as the targeting ligand and incorpo-
rating myristic acid for therapeutic delivery or as an 
excipient. This targeted construct could also be a car-
rier for other reperfusion injury therapeutics, such as 
dexamethasone, which if delivered systemically has 
significant adverse consequences.[28] 
Combining this information to create a nano-
construct is a logical approach and the demonstra-
tions here indicate that the fabrication of such a ra-
tionally designed nanoconstruct is possible. Toxicity 
is a concern for optical imaging agents based on 
quantum dots because many demonstrations of the 
potential of QD imaging used heavy metal-based 
QDs. Investigations into properly using heavy metal 
based quantum dots (generation 1 QDs) are still on-
going and are not yet conclusive as to the nature of 
toxicity in humans. SiQDs have been suggested as a 
suitable replacement for first-generation heavy met-
al-based quantum dots because they reduce the tox-
icity concerns and maintain their promise as optical 
imaging agents.  
SiQDs have been used for cancer application 
such as tumor targeting. Here, we use knowledge of 
that design to show that the information from metab-
olomics and proteomics can be used to create a po-
tential theranostic. The rational design includes the 
use of amine terminated DSPE-PEG that allows for 
further functionalization of the nano-construct. FTIR 
verifies that hyaluronic acid is present on the surface 
of the nanoparticle. We have previously demonstrat-
ed that CD44 can be targeted with hyaluronic 
acid.[29] The myristic acid in the core of the nanocon-
struct is released at a slow rate however this may be 
desirable for delayed release kinetics. The optical 
signal from the SiQDs is at 700nm, which is a desira-
ble wavelength for biological applications because it 
can provide a better signal to noise ratio than emission 
at visible wavelengths where tissue is less transpar-
ent. Implementation of this potential nanoconstruct 
will require testing and modification of the nanocon-
struct to evaluate its effectiveness, which will be re-
served for future studies in cells and animals. There is 
potential to expand the theranostic functionality of the 
nanoparticle by including other desirable modalities. 
Silicon quantum dots have already been combined 
with dyes, iron oxide, gold shells, siRNA and drugs in 
nanoformulations. 
The overall vision is to be able to obtain rich pa-
tient information with proteomic and metabolomics 
and rationally design platforms that can be evaluated 
and yield diagnosis and treatment information in a 
timely manner.  
Limitations 
This experiment was performed on a small sam-
ple size (n=33) with the potential for variability due to 
uncontrollable factors. The inability to perform mul-
tiple parallel MS experiments on the same samples 
limits the reproducibility of results. An additional 
limitation was the fact that the effects of pharmaco-
logical agents (heparin and glyceryl trinitrate) ad-
ministered in conjunction with PCI cannot be easily 
distinguished from that of ischemia induced by bal-
loon inflation during PCI. Optical imaging can suffer 
from poor tissue penetration and biological autofluo-
rescence which would limits its use in imaging the 
heart, however we use particle that emit at 700nm, a 
wavelength that has the advantage of reduced auto-
fluorescence, reduced tissue scattering and greater 
depth of penetration.[30] It is also quite plausible that 
the nanoconstruct will identify peripheral circulating 
blood cells which could be used for diagnostic imag-
ing through skin or blood assays. 
Conclusion 
This mechanistic study has demonstrated a 
method for metabolomic profiling of plasma and in-
tegrating this with proteomic data. This method has 
value in identifying novel biomarkers of disease and 
elucidating disease mechanisms through a holistic 
network analysis and in guiding development of 
novel therapeutic targets and compounds. These re-
sults are consistent with reports from independent 
laboratories. We have demonstrated the feasibility of 
using this data to construct a nanotheranostic that can 
be used for targeted imaging and therapy purposes. 
Supplementary Material 
Table S1-S2, Fig.S1–S2. 
http://www.thno.org/v03p0719s1.pdf 
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